Advertisement

Diabetologia

, Volume 60, Issue 4, pp 758–759 | Cite as

Erratum to: Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes

  • Emily J. GallagherEmail author
  • Zara Zelenko
  • Aviva Tobin-Hess
  • Ulrich Werner
  • Norbert Tennagels
  • Derek LeRoith
Erratum
  • 1.4k Downloads

Erratum to: Diabetologia

DOI 10.1007/s00125-016-4000-x

Unfortunately, there is an error in Fig. 1 and its accompanying legend. For the M1 metabolite, there should be no ‘R’ at position B31, and the third sentence of the legend has now been amended in line with this change. In addition, the final sentence of the legend has also been amended to explain the structures of insulin degludec and detemir more clearly.
Fig. 1

Amino acid sequences of human insulin and insulin analogues. Human insulin comprises an A chain with 21 amino acids (AAs) and a B chain with 30 AAs. A box around the AA letter indicates that the AA is altered, removed or added in the analogue compared with human insulin. Insulin glargine is metabolised to the M1 metabolite by removal of the two C-terminal arginine residues. A21Gly,DiD-Arg has the same AA sequence as insulin glargine, but the C-terminal arginines of parent insulin glargine are l-isomers (highlighted in bold font), and are d-isomers in non-metabolisable glargine (highlighted in grey). AspB10 insulin has an AA substitution of aspartic acid in place of histidine at position 10 on the B chain. K+ at position 29 on the B chain of insulin degludec and insulin detemir indicates the linkage of a hexadecandioic acid side chain via a glutamic acid spacer (degludec), or a tetradecanoic acid (detemir)

The correct version of Fig. 1 and the legend are shown overleaf.

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Emily J. Gallagher
    • 1
    Email author
  • Zara Zelenko
    • 1
  • Aviva Tobin-Hess
    • 1
  • Ulrich Werner
    • 2
  • Norbert Tennagels
    • 2
  • Derek LeRoith
    • 1
  1. 1.Division of Endocrinology, Diabetes and Bone Diseases, Department of MedicineIcahn School of Medicine at Mount SinaiNew YorkUSA
  2. 2.Diabetes Research & Translational Medicine, Insulin BiologySanofi-Aventis Deutschland GmbHFrankfurt am MainGermany

Personalised recommendations